New Report
Biotechnology and Pharmaceuticals
September 17, 2012
» See all the topics and companies covered
-
Emerging-Growth Opportunities in Oncology Biotech
Boris Peaker
-
Hepatitis C Therapies Propel Growth in Biotech
Matthew Roden
-
U.S. Biotech Valuations Appear Attractive Despite Earlier Run
Jim Birchenough
-
PDL BioPharma, Inc. (PDLI)
John P. McLaughlin
-
Cyclacel Pharmaceuticals, Inc. (CYCC)
Spiro Rombotis
-
Rigel Pharmaceuticals, Inc. (RIGL)
Raul R. Rodriguez
-
Hadasit Bio-Holdings Ltd. (HADSY)
Ophir Shahaf










